The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
